Acadia Pharmaceuticals ACAD Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Acadia Pharmaceuticals's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Acadia Pharmaceuticals's additional paid-in capital?
- Acadia Pharmaceuticals (ACAD) reported additional paid-in capital of $3.06B in Q1 2026.
- How has Acadia Pharmaceuticals's additional paid-in capital changed year-over-year?
- Acadia Pharmaceuticals's additional paid-in capital increased by 3.7% year-over-year, from $2.95B to $3.06B.
- What is the long-term trend for Acadia Pharmaceuticals's additional paid-in capital?
- Over 5 years (2020 to 2025), Acadia Pharmaceuticals's additional paid-in capital has grown at a 3.1% compound annual growth rate (CAGR), from $2.61B to $3.04B.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.